WOW! READ THIS NOW
Get in before it's to late!! RE:RE:WOW! READ THIS NOW This prospective test with THRM's partner Orpheus is in the early stages. If this saliva test is successful, it will be far superior and more user friendly to the nasal tests currently in the market. Other COVID test kit producers like MedMira (MIR.V) (MMIRF) and Sona Nanotech Inc. (SONA.CN) (SNANF) trade at very lofty valuations. MIR has an approximate $300 million market cap and SONA $860 million market cap. A $0.75 stock price on THRM is less than $150 million market cap even when including the most recent financing. We think this is a fair valuation relative to these peers while in the development stage of the test. Of course, upon successful deployment, the Orpheus test should lead to a market cap similar to these other companies as long as global COVID test demand remains high. Disclosure: We are long THRM.V